Nepal
Tuberculosis profile
Population  2012 27 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.5 (2.5–9.8) 20 (9–36)
Mortality (HIV+TB only) 0.23 (0.2–0.26) 0.83 (0.73–0.95)
Prevalence  (includes HIV+TB) 66 (29–120) 241 (106–429)
Incidence  (includes HIV+TB) 45 (37–53) 163 (135–195)
Incidence (HIV+TB only) 1.1 (0.94–1.4) 4.2 (3.4–5)
Case detection, all forms (%) 78 (66–95)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 15 057 (46) Relapse 2 280 (84)
Smear-negative 9 128 (28) Treatment after failure 234 (9)
Smear-unknown / not done 0 (0) Treatment after default 206 (8)
Extrapulmonary 7 865 (24) Other 0 (0)
Other 865 (3)      
Total new 32 915   Total retreatment 2 720  
           
Other (history unknown) 0        
Total new and relapse 35 195   Total cases notified 35 635  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.1    
Age < 15 460    
Laboratories 2012
Smear (per 100 000 population) 1.9
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 90   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 91  
Retreatment 85  
TB/HIV 2012 Number (%)
TB patients with known HIV status 15 057 (42)
HIV-positive TB patients 217 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 217 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 217 (100)
HIV-positive people screened for TB 3 673  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.3 (1.3–3.8) 15 (10–23)
MDR-TB cases among notified pulmonary
TB cases
570 (320–950) 420 (270–620)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 188 (1%) 640 (24%) 864
Laboratory-confirmed MDR-TB cases 25 313 354
Patients started on MDR-TB treatment     251
Financing TB control 2013
National TB programme budget (US$ millions) 8.8
% Funded domestically 8%
% Funded internationally 92%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data